Literature DB >> 19660877

Revisiting the possibility of serious adverse events from the whole cell pertussis vaccine: were metabolically vulnerable children at risk?

Kumanan Wilson1, Beth Potter, Douglas Manuel, Jennifer Keelan, Pranesh Chakraborty.   

Abstract

In the early 1980's concerns about the safety of the whole cell pertussis vaccine in the United States resulted in declining vaccination rates and the withdrawal of multiple vaccine providers from the market. While the possibility of inflammation and febrile reactions to the vaccine were acknowledged by public health authorities, parents also claimed the vaccine was associated with sudden infant death syndrome and encephalopathy. Epidemiological studies examining this question, however, consistently failed to identify an association. We argue that these reactions may have occurred in metabolically vulnerable children, specifically those with defects in fatty acid oxidation. In these children the combination of anorexia and fever that could be caused by the vaccine may have resulted in hypoglycemic episodes and possibly death. We believe that this association was not detected because these conditions were not recognized at the time and because these conditions are uncommon. Nevertheless, at a population level, enough events could have occurred to cause concern amongst parents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660877     DOI: 10.1016/j.mehy.2009.07.014

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

1.  Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.

Authors:  S Elizabeth Williams; Barbara A Pahud; Claudia Vellozzi; Peter D Donofrio; Cornelia L Dekker; Neal Halsey; Nicola P Klein; Roger P Baxter; Colin D Marchant; Philip S Larussa; Elizabeth D Barnett; Jerome I Tokars; Brian E McGeeney; Robert C Sparks; Laurie L Aukes; Kathleen Jakob; Silvia Coronel; James J Sejvar; Barbara A Slade; Kathryn M Edwards
Journal:  Vaccine       Date:  2011-09-03       Impact factor: 3.641

2.  Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.

Authors:  Agricola Joachim; Asli Bauer; Sarah Joseph; Christof Geldmacher; Patricia J Munseri; Said Aboud; Marco Missanga; Philipp Mann; Britta Wahren; Guido Ferrari; Victoria R Polonis; Merlin L Robb; Jonathan Weber; Roger Tatoud; Leonard Maboko; Michael Hoelscher; Eligius F Lyamuya; Gunnel Biberfeld; Eric Sandström; Arne Kroidl; Muhammad Bakari; Charlotta Nilsson; Sheena McCormack
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

Review 3.  Non-primate animal models for pertussis: back to the drawing board?

Authors:  Nevio Cimolai
Journal:  Appl Microbiol Biotechnol       Date:  2022-02-01       Impact factor: 4.813

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.